Publish in OALib Journal
APC: Only $99
The goal of this research was to study how people feel about sharing personal information on social networks. The research was done by interviews; 50 people were interviewed, mostly from mainland China, Hong Kong, and Finland. This paper presents the included 12 questions and discusses the collected answers. It was discovered, e.g., that 38 out of the 50 answerers use social media every day and share versatile personal information on the Internet. Half of the answerers also share information about other people on the Internet. It was also discovered that compared to male answerers, the female answerers were more active in sharing information about other people. There was a significant variety in opinions: what should be the age limit for sharing personal information online, while 22 out of the 50 answerers felt that there is no need for an age limit at all. According to the answers, only a few people use social media for making new friends. Instead, an important reason for using social media is that their existing friends are using. An interesting finding was that the answerers see the Internet as a part of the real world; the privacy that you have on the Internet is the privacy that you have in the real world.
Objective: To evaluate
patient satisfaction with insulin glargine. Design: Multicentre observational
registry. Data were collected at baseline/inclusion visit, and 12 and 24 weeks.
Setting: Physicians in Hong Kong, who managed type 2 diabetes patients and had
>5 years’ experience in using insulin glargine. Patients: People with type 2
diabetes, new to insulin, aged 18 - 75 years, who were previously being treated
with ≤3 oral antidiabetes drugs (OAD) and had HbA1c > 7%, and in whom the physicians had chosen to prescribe
glargine for the first time. Main outcome measures: Treatment satisfaction
assessed by Diabetes Treatment Satisfaction Questionnaire (DTSQs), glycaemic
control (fasting blood glucose and HbA1c) and adverse events. Results: Between
April 2010-October 2011, 41 patients completed the study. Average duration of
diabetes and OAD therapy was 7.8 ± 8.0 years and 6.7 ± 7.4 years, respectively.
The global DTSQs treatment satisfaction scores improved from 20.9 at baseline
to 28.4 (p < 0.05) at the end of 24 weeks insulin glargine treatment.
Analysis of DTSQs scores showed a decrease in perceived frequency of
hyperglycaemia (4.1 to 1.9, p < 0.001) and hypoglycemia (2.2 to 1.5, p =
0.079). Perceived convenience (0.60, p < 0.025) and flexibility (0.9, p <
0.009) were also improved from baseline. Reduction in mean HbA1c (10.2% ± 2.2%
to 7.0% ± 1.0%) and fasting blood glucose (10.9 ± 4.0 mmol/L to 6.4 ± 1.8
mmol/L) from baseline to study termination was significant (p < 0.05).
Almost half (48.7%) of patients achieved HbA1c ≤ 7.0%, while 26.0% patients had
FBG < 5.6 mmol/L. In total, 9 (22.0%) patients experienced at least one
hypoglycemia event; there were no reports of severe hypoglycaemia. Conclusions:
Despite a small number of subjects completed in this study, the study
demonstrated clearly that the addition of insulin glargine to OAD therapy in
diabetes management improved treatment satisfaction and perceived frequency of
hyper-and hypoglycaemia together with glycaemic control close to recommended
target without severe side-effects in this cohort of patients in Hong Kong.